Lexicon Pharmaceuticals Current Valuation vs. Shares Outstanding

LXRX Stock  USD 0.69  0.02  2.82%   
Based on Lexicon Pharmaceuticals' profitability indicators, Lexicon Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Lexicon Pharmaceuticals' ability to earn profits and add value for shareholders. At this time, Lexicon Pharmaceuticals' Days Sales Outstanding is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 326.90 in 2024, whereas Price To Sales Ratio is likely to drop 208.67 in 2024. At this time, Lexicon Pharmaceuticals' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Income Tax Expense is likely to rise to about 405.4 K in 2024, despite the fact that Operating Income is likely to grow to (163.2 M).
For Lexicon Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lexicon Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lexicon Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lexicon Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lexicon Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexicon Pharmaceuticals. If investors know Lexicon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexicon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.63)
Earnings Share
(0.71)
Revenue Per Share
0.018
Quarterly Revenue Growth
9.802
Return On Assets
(0.44)
The market value of Lexicon Pharmaceuticals is measured differently than its book value, which is the value of Lexicon that is recorded on the company's balance sheet. Investors also form their own opinion of Lexicon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lexicon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexicon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lexicon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexicon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexicon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexicon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Lexicon Pharmaceuticals Shares Outstanding vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Lexicon Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Lexicon Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Lexicon Pharmaceuticals is rated below average in current valuation category among its peers. It is rated second overall in shares outstanding category among its peers creating about  3.60  of Shares Outstanding per Current Valuation. Common Stock Shares Outstanding is likely to rise to about 232.2 M in 2024. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexicon Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Lexicon Current Valuation vs. Competition

Lexicon Pharmaceuticals is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 7.07 Billion. Lexicon Pharmaceuticals claims roughly 100.53 Million in current valuation contributing just under 2% to equities under Health Care industry.

Lexicon Shares Outstanding vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Lexicon Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
100.53 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Lexicon Pharmaceuticals

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
361.49 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.

Lexicon Shares Outstanding Comparison

Lexicon Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.

Lexicon Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Lexicon Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lexicon Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Lexicon Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Lexicon Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income31 K32.5 K
Operating Income-171.8 M-163.2 M
Net Loss-177.1 M-168.3 M
Income Tax Expense386.1 K405.4 K
Income Before Tax-177.1 M-168.3 M
Total Other Income Expense Net-5.4 M-5.6 M
Net Loss-157.9 M-165.7 M
Non Operating Income Net Other1.8 M1.9 M
Net Loss-117.2 M-123.1 M
Interest Income6.2 M6.5 M
Net Interest Income-2.6 M-2.7 M
Change To Netincome10.4 M8.8 M
Net Loss(0.80)(0.84)
Income Quality 0.91  0.96 
Net Income Per E B T 0.91  0.54 

Lexicon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Lexicon Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lexicon Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lexicon Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Lexicon Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Use Investing Themes to Complement your Lexicon Pharmaceuticals position

In addition to having Lexicon Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Real Estate Thematic Idea Now

Real Estate
Real Estate Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Real Estate theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.